Evolus Stock Price, News & Analysis

Evolus, Inc. (NASDAQ: EOLS), a performance beauty firm, announces participation in the SVB Securities Global Biopharma Conference.

Date: February 14, 2023

Time: 11:20-11:50 am ET

Management will discuss their innovative, customer-centric business model and flagship product, Jeuveau^®, which is the first neurotoxin dedicated to aesthetics. An audio webcast will be available on Evolus' investor relations website, with a replay accessible for 90 days post-event.

Evolus (NASDAQ: EOLS) released interim data from its Phase II clinical study of a new "extra-strength" formulation of Jeuveau® at the IMCAS World Congress in Paris. The 40U formulation achieved a notable 6-month effect on Glabellar Lines with a favorable safety profile; no serious adverse events were reported, and 88% of adverse events were mild. The trial, involving 150 patients, aims to evaluate the formulation's efficacy and safety, with final results expected in the second half of 2023. This advancement represents a potential expansion of Evolus' offerings in the aesthetic neurotoxin market.

Evolus, Inc. (NASDAQ: EOLS) announced regulatory approval for Nuceiva® (prabotulinumtoxinA) in Australia, aimed at treating moderate to severe glabellar lines. This approval represents a significant opportunity in one of the largest aesthetic neurotoxin markets outside the U.S. CEO David Moatazedi highlighted the importance of international expansion, aiming for $500 million in total revenue by 2028. Nuceiva is already available in Great Britain and Canada. Evolus plans to launch Nuceiva in Australia in the second half of 2023 following launches in Germany and Austria.

Evolus, Inc. (NASDAQ: EOLS) is set to present interim findings from a Phase 2 study on its neurotoxin product, Jeuveau (prabotulinumtoxinA-xvfs), at the 2023 International Master Course on Aging Science on January 28, 2023 in Paris. The presentation, led by Dr. Rui Avelar, will compare a new 'extra-strength' dose of Jeuveau to existing formulations and Botox for treating moderate to severe glabellar lines. The trial is expected to conclude in H1 2023, with final results to follow later this year. An investor webcast on January 30, 2023 will discuss these findings further.

Evolus, Inc. (NASDAQ: EOLS) reported strong preliminary financial figures for Q4 2022 and full-year 2022. Q4 net revenue reached approximately $43.6 million, a 26% increase year-over-year, while full-year revenue was about $148.6 million, a 49% rise. The company anticipates 2023 net revenue will be between $180 million and $190 million, with positive non-GAAP operating income expected in Q4 2023. Evolus also estimates organic net revenue could hit $500 million by 2028. The company continues to experience market share growth, particularly in the neurotoxin sector.

Evolus, Inc. (NASDAQ: EOLS) has announced the extension of the second tranche of its $125 million term loan facility, now available until December 31, 2023. This tranche amounts to $50 million and maintains all previous terms, including interest payments based on the 3-month LIBOR plus 8.5%. The company continues to anticipate reaching cash flow breakeven with its existing cash resources while focusing on expanding its product portfolio. Evolus aims to capitalize on the growing aesthetic neurotoxin market with a customer-centric approach.

Pipeline Medical has announced the addition of Jeuveau® (prabotulinumtoxinA-xvfs) by Evolus (NASDAQ: EOLS) to its offerings. Jeuveau® is a popular botulinum toxin used for aesthetic improvements, particularly for frown lines. With significant market penetration since its launch in 2019, over 8,800 practices have adopted the product, achieving a reorder rate of over 70%. Pipeline Medical aims to enhance access to Jeuveau® through co-branded marketing and competitive pricing, further solidifying its position as a trusted supplier in the MedTech marketplace.

Evolus reported a 27% increase in sales for Q3 2022, reaching $33.9 million, primarily driven by a successful promotional campaign named ‘Switch Your Tox’. The campaign generated $3.5 million in incremental deferred revenue and reported a record of 100,000 consumer redemptions. Evolus maintains its 2022 revenue guidance of $143 to $150 million, projecting year-over-year growth of around 50%. The company's cash position stood at $65.6 million, expected to fund operations to breakeven, as operating expenses decreased to $51.8 million.

Evolus, Inc. (NASDAQ: EOLS), a company focused on beauty products, is participating in two investment conferences in November 2022. The first event is the Stifel 2022 Healthcare Conference on November 15, 2022, from 8:35-9:05 am ET. The second event is the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, from 11:45-12:05 pm ET. Audio webcasts of both events will be available on Evolus’ investor relations website, with replays accessible for 90 days.